Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Appointed director
Inv. presentation
Midatech Pharma US Inc. (DARA) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/04/2015 8-K Quarterly results
12/02/2015 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "DARA BioSciences Announces Stockholder Approval of Merger with Midatech RALEIGH, NC -- – December 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC and certain other parties thereto. Pursuant to the merger agreement, upon completion of the contemplated merger, DARA will become a wholly owned subsidiary of Midatech. The merger remains subject to customary closing conditions and is expected to close in the next week. ..."
11/19/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/18/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/18/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/12/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/09/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/02/2015 425 Form 425 - Prospectuses and communications, business combinations
11/02/2015 10-Q Quarterly Report for the period ended September 30, 2015
11/02/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/02/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Third Quarter 2015 Results Record Revenues for Q3 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – November 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results. Third Quarter 2015 Financial Snapshot DARA reported net revenues of $1.181 million for the third quarter ended September 30, 2015 based on gross product sales in excess of $1.5 million, as compared to net revenues of $597.8 ..."
10/22/2015 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition
08/12/2015 10-Q Quarterly Report for the period ended June 30, 2015
08/12/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Second Quarter 2015 Results Record Revenues for Q2 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – August 12 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results. Second Quarter 2015 Financial Snapshot DARA reported net revenues of $990.8 thousand for the second quarter ended June 30, 2015 based on gross product sales in excess of $1.4 million, as compared to net revenues of $409.4 thousan..."
08/12/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
08/12/2015 425 Form 425 - Prospectuses and communications, business combinations
06/05/2015 425 Form 425 - Prospectuses and communications, business combinations
06/05/2015 425 Form 425 - Prospectuses and communications, business combinations
06/05/2015 425 Form 425 - Prospectuses and communications, business combinations
06/04/2015 425 Form 425 - Prospectuses and communications, business combinations
06/04/2015 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among DARA BioSciences, Inc., Midatech Pharma, PLC, Merlin Acquisition Sub, Inc., Duke Acquisition Sub, Inc. and Shareholder Representative Services, LLC",
"Form of Contingent Value Rights Agreement",
"Form of Voting Agreement",
"- DARA’s Commercial Organization Key Driver of Agreement - Combined Organization Provides Pipeline of Oncology Products for U.S. Commercialization"
06/04/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
05/19/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/13/2015 10-Q Quarterly Report for the period ended March 31, 2015
05/13/2015 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FIRST QUARTER 2015 RESULTS Company to provide inaugural 2015 revenue guidance based upon continued commercial progress Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its first quarter 2015 results. First Quarter 2015 Financial Snapshot DARA reported net revenues of $652.2 thousand for the first quarter ended March 31, 2015 based on gross product sales in excess of $850 thousand, as compared to net revenues of $161.5 thousand for the first quarter ended March 31, 2014, a year over year increase of 304%. The incre..."
03/10/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "DARA BIOSCIENCES ANNOUNCES THE ACQUISITION OF EXCLUSIVE NORTH AMERICAN RIGHTS TO ORAVIG® , FROM ONXEO S.A. - DARA signs agreement with Mission Pharmacal to promote Oravig in the Primary Care Market - DARA to promote Oravig in the Oncology Market - Deal significantly strengthens DARA’s oncology supportive care portfolio"
03/03/2015 10-K Annual Report for the period ended December 31, 2014
03/03/2015 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 RESULTS Strong Annual Revenue Growth Driven By Execution of Commercial Sales Strategy Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its financial results for the fourth quarter and full year ended December 31, 2014. The Company also provided a business update on its fourth quarter 2014 operational and commercial highlights. Fourth Quarter 2014 Financial Snapshot DARA reported net revenues of $1.89 million for the full year ended December 31, 2014 based on gross product sales of ..."
02/13/2015 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2015 SC 13G/A ALPHA CAPITAL ANSTALT reports a 5% stake in DARA BIOSCIENCES, INC.
01/20/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between DARA BioSciences, Inc. and Christopher G. Clement",
"Employment Agreement, by and between DARA BioSciences, Inc. and David J. Drutz",
"Employment Agreement, by and between DARA BioSciences, Inc. and David Tousley"
01/06/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Contact:"
12/15/2014 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Exchange and Amendment Agreement",
"Common Stock Purchase Warrant with respect to 125,000 shares of common stock of DARA BioSciences, Inc",
"Common Stock Purchase Warrant with respect to 175,000 shares of common stock of DARA BioSciences, Inc"
11/21/2014 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy